Log in
Enquire now
‌

US Patent 10517886 Drug formulations

Patent 10517886 was granted and assigned to Astex Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Astex Pharmaceuticals
Astex Pharmaceuticals
Current Assignee
Astex Pharmaceuticals
Astex Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10517886
Date of Patent
December 31, 2019
Patent Application Number
15879802
Date Filed
January 25, 2018
Patent Citations Received
‌
US Patent 11058705 Drug formulations
‌
US Patent 10858386 Drug compound and purification methods thereof
Patent Primary Examiner
‌
Patrick T. Lewis
Patent abstract

The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10517886 Drug formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.